Received Dec 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (HIBERIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 742G5 | — |
patient received the diluent component of Hiberix without it being mixed with the antigen; patient received the diluent component of Hiberix without it being mixed with the antigen; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Hib (Hiberix) (batch number 742G5) for prophylaxis. On an unknown date, the patient received Hiberix. On an unknown date, an unknown time after receiving Hiberix, the patient experienced inappropriate preparation of medication (Verbatim: patient received the diluent component of Hiberix without it being mixed with the antigen) and inappropriate dose of vaccine administered (Verbatim: patient received the diluent component of Hiberix without it being mixed with the antigen). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-DEC-2025 A Medical Assistant (MA) reported that a patient received the diluent component of Hiberix (Saline) without it being mixed with the antigen.